Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated

Amicus Therapeutics (FOLD) reported third-quarter 2024 adjusted earnings of 10 cents per share, beating the Zacks Consensus Estimate of 8 cents. The company had incurred a loss of 1 cent per share in the year-ago quarter.The year-over-year improvement can be attributed to higher revenues from Galafold (migalastat) sales and incremental revenues from the sale of the newly approved combo drug, Pombiliti + Opfolda.Revenues in the third quarter totaled $141.5 million, up 37% year over year on a reported basis a ...